Thiamine ion
As of the edition of 20 October 2026, Thiamine ion is a small molecule: marketed, first approved in 1950 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- M.V.I.-12 Adult
- First approved
- 1 May 1950 (ES)
- Approvals on record
- 31 in 5 regions
- Holder of the most recent approval
- B. Braun Medical; 14 holders in all
- Registered trials
- 49, 7 stopped early
- Disease areas
- Nutrition and metabolism; Infections; Heart and blood vessels; Nervous system; Hormones; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 9 | 1 | 2 |
| Phase 1 | 4 | 2 | 1 | 1 |
| Phase 2 | 15 | 10 | 2 | 2 |
| Phase 3 | 8 | 4 | 1 | 1 |
| Phase 4 | 9 | 6 | 0 | 1 |
| All trials | 49 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bayer | Applicant | 1967 to now |
| B. Braun Medical | Later holder | 2024 to now |